PT  - JOURNAL ARTICLE
AU  - Dagpunar, John
TI  - Sensitivity of UK Covid-19 deaths to the timing of suppression measures and their relaxation
AID  - 10.1101/2020.05.09.20096859
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.09.20096859
4099  - http://medrxiv.org/content/early/2020/05/18/2020.05.09.20096859.short
4100  - http://medrxiv.org/content/early/2020/05/18/2020.05.09.20096859.full
AB  - In this paper I examine the sensitivity of total UK Covid-19 deaths and the demand for intensive care and ward beds, to the timing and duration of suppression periods during a 500 day period. This is achieved via a SEIR model. Using an expected latent period of 4.5 days and infectious period of 3.8 days, R0 was first estimated as 3.18 using observed death rates under unmitigated spread and then under the effects of the total lockdown (R0 =0.60) of 23 March. The case fatality rate given infection is taken as 1%. Parameter values for mean length of stay and conditional probability of death for ICU and non-ICU hospital admissions are guided by Ferguson et al.(2020). Under unmitigated spread the model predicts around 600,000 deaths in the UK. Starting with one exposed person at time zero and a suppression consistent with an R0 of 0.60 on day 72, the model predicts around 39,000 deaths for a first wave, but this reduces to around 11,000 if the intervention takes place one week earlier. If the initial suppression were in place until day 200 and then relaxed to an R0 of 1.5 between days 200 and 300, to be followed by a return to an R0 of 0.60, the model predicts around 43,000 deaths. This would increase to around 64,000 if the release from the first suppression takes place 20 days earlier. The results indicate the extreme sensitivity to timing and the consequences of even small delays to suppression and premature relaxation of such measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo Funding. Personal ResearchAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCalculations available on request to author